Real from start to finish: making the most of real-world data from disease registries across the product lifecycle
As real-world evidence (RWE) is increasingly being used to inform guidance and approval decisions by regulators, health technology assessment (HTA) bodies, and payers across the US, Europe, and other jurisdictions, biotech and pharma are investing more into generating...
Key takeaways from ISPOR Europe 2023
ISPOR Europe was the busiest we’ve ever seen it. Those few days were jam-packed with engaging plenary sessions, educational symposia, poster research, and networking opportunities. Many fruitful conversations were had, with the team contributing the following rundown...
The power of trial interviews
In October 2023, the US Food and Drug Administration (FDA) released their industry guidance for benefit-risk assessment of novel products¹, in which the role of patient experience data was highlighted in its capacity to “inform nearly every aspect of FDA’s...
ISOQOL 30th Annual Conference take-aways
The International Society for Quality of Life Research (ISOQOL) 30th Annual Conference took place last month in Calgary, providing the opportunity for researchers, healthcare professionals, industry representatives, and patient research partners to explore the use of...
